2024
Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor
Brösecke F, Pfau A, Ermer T, Dein Terra Mota Ribeiro A, Rubenbauer L, Rao V, Burlein S, Genser B, Reichel M, Aronson P, Coca S, Knauf F. Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor. Scientific Reports 2024, 14: 11323. PMID: 38760468, PMCID: PMC11101424, DOI: 10.1038/s41598-024-61808-7.Peer-Reviewed Original ResearchConceptsIL-16 levelsIL-16Dialysis patientsCardiovascular eventsConcentrations of IL-16Kidney failureUremic toxinsCardiovascular diseaseCompared to healthy individualsPlasma oxalate concentrationActivated immune cellsAssociated with cardiovascular diseaseIL-16 concentrationCytokine IL-16Cardiovascular risk factorsNo significant associationPlasma oxalateInflammatory markersImmune cellsCytokine concentrationsInterleukin-16US patientsCohort 1Cardiovascular outcomesHealthy individualsOxalate Metabolism: From Kidney Stones to Cardiovascular Disease
Hawkins-van der Cingel G, Walsh S, Eckardt K, Knauf F. Oxalate Metabolism: From Kidney Stones to Cardiovascular Disease. Mayo Clinic Proceedings 2024, 99: 1149-1161. PMID: 38762815, DOI: 10.1016/j.mayocp.2024.02.006.Peer-Reviewed Original Research
2023
Design Research to Embed mHealth into a Community-Led Blood Pressure Management System in Uganda: Protocol for a Mixed Methods Study
Schwab J, Wachinger J, Munana R, Nabiryo M, Sekitoleko I, Cazier J, Ingenhoff R, Favaretti C, Pillai V, Weswa I, Wafula J, Emmrich J, Bärnighausen T, Knauf F, Knauss S, Nalwadda C, Sudharsanan N, Kalyesubula R, McMahon S. Design Research to Embed mHealth into a Community-Led Blood Pressure Management System in Uganda: Protocol for a Mixed Methods Study. JMIR Research Protocols 2023, 12: e46614. PMID: 38032702, PMCID: PMC10722357, DOI: 10.2196/46614.Peer-Reviewed Original ResearchINTERNATIONAL REGISTERED REPORT IDENTIFIERIntervention prototypeManagement of hypertensionHealth careChronic disease managementMixed-methods studyMobile health interventionsResource-constrained settingsHealth system challengesUncontrolled hypertensionAntihypertensive medicationsGerman RegistryHypertension managementRisk factorsClinical trialsCardiovascular diseaseHypertensionMethods studyBasic health careMedicationsHealth interventionsConcurrent trialsSuch diseasesDisease managementPrivate facilities
2022
Hemodialysis and biotransformation of erythrocyte epoxy fatty acids in peripheral tissue
Liu T, Dogan I, Rothe M, Kunz J, Knauf F, Gollasch M, Luft F, Gollasch B. Hemodialysis and biotransformation of erythrocyte epoxy fatty acids in peripheral tissue. Prostaglandins Leukotrienes And Essential Fatty Acids 2022, 181: 102453. PMID: 35633593, DOI: 10.1016/j.plefa.2022.102453.Peer-Reviewed Original ResearchConceptsRed blood cellsHD treatmentHemodialysis treatmentEnd-stage renal disease patientsHydroxyeicosatetraenoic acidHydroxyeicosapentaenoic acidSingle hemodialysis treatmentChronic kidney diseaseRenal disease patientsRenal replacement therapyFatty acid statusVenous blood samplesHydroxydocosahexaenoic acidEpoxy fatty acidsCause of mortalityLOX pathwayRenal failureFatty acidsKidney diseaseDisease patientsVenous bloodCardiovascular functionAcid statusArteriovenous differenceCardiovascular disease